Cannabis use among CVS hospitalizations was linked to shorter stays and fewer readmissions, possibly due to CHS misclassification
In a nationwide analysis of over 35,000 cyclical vomiting syndrome hospitalizations, cannabis use was associated with shorter hospital stays and 37% lower 30-day readmissions, likely because some cases were actually cannabinoid hyperemesis that improved with cessation.
Quick Facts
What This Study Found
Among 35,055 CVS admissions (NIS), cannabis use was associated with reduced length of stay (adjusted mean difference -0.53 days) and 37% lower 30-day readmissions (aHR 0.63). The authors suggest this paradoxical finding likely reflects cannabinoid hyperemesis syndrome (CHS) cases miscoded as CVS, where cannabis cessation during hospitalization improved outcomes.
Key Numbers
35,055 NIS admissions; 31,240 NRD admissions; 6.4% readmitted within 30 days; cannabis use: LOS reduced by 0.53 days (95% CI -0.68 to -0.38); 30-day readmission aHR 0.63 (95% CI 0.54-0.73)
How They Did This
Retrospective nationwide analysis using weighted data from the National Inpatient Sample (NIS, 35,055 admissions) and National Readmission Database (NRD, 31,240 admissions). Multivariate regression assessed predictors of length of stay and 30-day readmission among patients with primary CVS diagnosis.
Why This Research Matters
The overlap between CVS and CHS is a significant diagnostic challenge. This study highlights how ICD coding limitations obscure the true relationship between cannabis and cyclic vomiting.
The Bigger Picture
The lack of a specific ICD-10 code for CHS means an unknown number of CHS cases are coded as CVS, confounding research on both conditions and potentially leading to inappropriate treatment approaches.
What This Study Doesn't Tell Us
Administrative data cannot distinguish CVS from CHS; cannabis use identification depends on ICD coding which may be incomplete; cannot determine if patients ceased cannabis during hospitalization; no data on cannabis use patterns or amounts
Questions This Raises
- ?How many CVS hospitalizations are actually CHS?
- ?Would implementing specific CHS ICD codes improve diagnostic accuracy and treatment?
- ?What proportion of the reduced readmissions is attributable to cannabis cessation?
Trust & Context
- Key Stat:
- 37% lower readmission risk with cannabis use (likely CHS misclassification)
- Evidence Grade:
- Large nationwide administrative database study with appropriate regression modeling, but fundamentally limited by inability to distinguish CVS from CHS.
- Study Age:
- 2024 study
- Original Title:
- Cannabis use and cyclical vomiting syndrome: An open debate.
- Published In:
- Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 56(2), 272-280 (2024)
- Authors:
- Kilani, Yassine(2), Aljabiri, Yazan, Arshad, Iqra, Alsakarneh, Saqr, Aldiabat, Mohammad, Castro Puello, Priscila, Vahanyan, Anush, Vikash, Fnu, Kumar, Vikash, Numan, Laith, Thor, Savanna
- Database ID:
- RTHC-05425
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Why would cannabis use improve CVS outcomes?
It probably does not. The authors suggest many of these "CVS" cases were actually cannabinoid hyperemesis syndrome (CHS), which improves when patients stop using cannabis. Hospitalization often involves temporary cannabis cessation, which would explain the shorter stays and fewer readmissions.
Why are CVS and CHS confused?
There is no specific ICD-10 code for CHS, so these cases get coded as CVS. Both conditions involve cyclic vomiting, making clinical differentiation difficult. The study authors call for specific CHS coding to improve differentiation between these conditions.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05425APA
Kilani, Yassine; Aljabiri, Yazan; Arshad, Iqra; Alsakarneh, Saqr; Aldiabat, Mohammad; Castro Puello, Priscila; Vahanyan, Anush; Vikash, Fnu; Kumar, Vikash; Numan, Laith; Thor, Savanna. (2024). Cannabis use and cyclical vomiting syndrome: An open debate.. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 56(2), 272-280. https://doi.org/10.1016/j.dld.2023.10.002
MLA
Kilani, Yassine, et al. "Cannabis use and cyclical vomiting syndrome: An open debate.." Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2024. https://doi.org/10.1016/j.dld.2023.10.002
RethinkTHC
RethinkTHC Research Database. "Cannabis use and cyclical vomiting syndrome: An open debate." RTHC-05425. Retrieved from https://rethinkthc.com/research/kilani-2024-cannabis-use-and-cyclical
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.